AstraZeneca’s Tagrisso improves overall survival in lung cancer in Phase 3 trial
AstraZeneca has said its cancer drug Tagrisso significantly improved overall survival in a Phase 3 study of patients with lung cancer.
The drug showed statistically significant and clinically meaningful improvement in overall survival in previously untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) mutations.
The safety and tolerability of Tagrisso was consistent with its established profile. The drug is currently approved in 74 countries including the US, Japan and the EU for 1st-line EGFRm metastatic NSCLC.
José Baselga, Executive Vice President, Oncology R&D said: “Today’s positive results show that Tagrisso provides an unprecedented survival outcome versus previous standard-of-care epidermal growth factor receptor tyrosine kinase inhibitors, reaffirming Tagrisso as the 1st-line standard-of-care for EGFR-mutated metastatic non-small cell lung cancer.”
The US Food and Drug Administration (FDA) has granted de novo marketing authorisation to the …
Kura Oncology has shared positive preclinical data which supports the development of its next-generation farnesyl …
AstraZeneca and Daiichi Sankyo have shared positive high-level results from the TROPION-Breast01 phase 3 trial, …